Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 19/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21938965 | 0.89 | DPP4 (0.42) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL25010712 | 0.89 | DPP4 (0.42) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL2760455 | 0.89 | DPP4 (0.42) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL5017003 | 0.84 | DPP4 (0.45) | DPP4DPP7DPP9DPP8 | |
| Trifluoroacetic Acid SCHEMBL20398316 | 0.82 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL6277604 | 0.80 | — | — | |
| SCHEMBL5017011 | 0.80 | — | — | |
| SCHEMBL14996198 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL29505595 | 0.79 | SMN1; SMN2 (0.41) | DPP4DPP7DPP9DPP8KCNH2 | |
| SCHEMBL31463704 | 0.79 | DPP4 (0.40) | DPP4DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-13 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | DPP4 3029/4885DPP7 2672/4885DPP9 3801/4885 |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | DPP4 3029/4885DPP7 2672/4885DPP9 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.